| Dr Maurine T Ladner, PHD, MP | |
|
400 Georgia Ave, Bogalusa, LA 70427-3866 | |
| (985) 732-6610 | |
| Not Available |
| Full Name | Dr Maurine T Ladner |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Prescribing (medical) |
| Location | 400 Georgia Ave, Bogalusa, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720224470 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TP0016X | Psychologist - Prescribing (medical) | MP-969 (Louisiana) | Secondary |
| 103TP0016X | Psychologist - Prescribing (medical) | 000969 (Louisiana) | Primary |
| Entity Name | Florida Parishes Human Services Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679128292 PECOS PAC ID: 0446578215 Enrollment ID: O20150408001452 |
News Archive
Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure - the leading cause of liver failure in the United States - by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal.
Melanoma patients using their smart phone to submit images of lesions to their specialists appears to be a safe and convenient form of follow-up after treatment.
How can counting cancer cells in the blood make a difference in treatment? Can a potent hormone that fuels some breast cancers be used to fire back against the disease? These critical questions are being answered via innovative laboratory and clinical research underway at Georgetown Lombardi Comprehensive Cancer Center. A renowned pharmacologist who discovered a leading treatment for cancer and a physician treating patients in cutting edge clinical trials will discuss these and other life-enhancing discoveries during Doctors Speak Out, a series of conversations with physicians and researchers on today's most pressing health issues.
Sweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (lanthanum carbonate), a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden will now become the Reference Member State in the EU Mutual Recognition Procedure for FOSRENOL, and this is the first step in securing marketing approval throughout Europe. A submission has also been made by Shire to gain marketing approval for FOSRENOL in the United States.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maurine T Ladner, PHD, MP 400 Georgia Ave, Bogalusa, LA 70427-3866 Ph: () - | Dr Maurine T Ladner, PHD, MP 400 Georgia Ave, Bogalusa, LA 70427-3866 Ph: (985) 732-6610 |
News Archive
Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure - the leading cause of liver failure in the United States - by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal.
Melanoma patients using their smart phone to submit images of lesions to their specialists appears to be a safe and convenient form of follow-up after treatment.
How can counting cancer cells in the blood make a difference in treatment? Can a potent hormone that fuels some breast cancers be used to fire back against the disease? These critical questions are being answered via innovative laboratory and clinical research underway at Georgetown Lombardi Comprehensive Cancer Center. A renowned pharmacologist who discovered a leading treatment for cancer and a physician treating patients in cutting edge clinical trials will discuss these and other life-enhancing discoveries during Doctors Speak Out, a series of conversations with physicians and researchers on today's most pressing health issues.
Sweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (lanthanum carbonate), a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden will now become the Reference Member State in the EU Mutual Recognition Procedure for FOSRENOL, and this is the first step in securing marketing approval throughout Europe. A submission has also been made by Shire to gain marketing approval for FOSRENOL in the United States.
› Verified 2 days ago